Alpha-1-antitrypsin modified process - Grifols

Drug Profile

Alpha-1-antitrypsin modified process - Grifols

Alternative Names: Alpha-1 MP - Grifols; Alpha-1 proteinase-inhibitor-modified process - Grifols; Alpha-1-antitrypsin IV - Grifols; Alpha-1-protease-inhibitor-modified process - Grifols; Alpha-antitrypsin modified process - Grifols; Alpha1-PI; Prolastin; Prolastin-C; Prolastin-C Liquid; TAL 6004

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Developer Grifols; Vifor Pharma
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase II Chronic fatigue syndrome; Type 1 diabetes mellitus

Most Recent Events

  • 25 Oct 2017 Grifols Therapeutics terminates a phase II trial for Type-1 diabetes mellitus (Newly-diagnosed, In children, In adolescents, In adults) in USA as week 52 primary endpoint results would be unaffected by follow-up data prior to week 104 (NCT02093221)
  • 22 Sep 2017 Registered for Alpha 1-antitrypsin deficiency in USA (IV, Liquid)
  • 22 Sep 2017 The commercial launch of Prolastin®-C Liquid is scheduled for 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top